Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ardelyx Inc

Healthcare US ARDX

5.42USD
-0.1(1.81%)

Last update at 2026-06-03T20:29:00Z

Day Range

5.315.60
LowHigh

52 Week Range

3.218.40
LowHigh

Fundamentals

  • Previous Close 5.52
  • Market Cap1461.67M
  • Volume3811211
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.91800M
  • Revenue TTM407.32M
  • Revenue Per Share TTM1.69
  • Gross Profit TTM 296.26M
  • Diluted EPS TTM-0.26

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -60.63000M -38.87000M -65.52000M -67.19900M -158.16100M
Minority interest - - - - -
Net income -61.59900M -39.13600M -66.06700M -67.20700M -158.16500M
Selling general administrative 337.23M 258.69M 134.40M 76.60M 72.30M
Selling and marketing expenses - - - - -
Gross profit 367.78M 283.06M 106.66M 48.04M 9.10M
Reconciled depreciation 3.06M 2.06M 1.29M 1.14M 1.44M
Ebit -32.23200M -18.77600M -56.64600M -63.75900M -154.34600M
Ebitda -29.17300M -16.71300M -55.35400M -62.12600M -153.65900M
Depreciation and amortization 3.06M 2.06M 1.29M 1.63M 0.69M
Non operating income net other - - - 1.63M 0.69M
Operating income -40.97700M -27.95000M -63.27600M -63.75900M -154.34600M
Other operating expenses 448.30M 361.56M 187.73M 115.92M 164.44M
Interest expense 28.40M 20.09M 8.87M 5.07M 4.50M
Tax provision 0.97M 0.27M 0.55M 0.00800M 0.00400M
Interest income - - - - -
Net interest income -28.39800M -20.09400M -8.87400M -5.07300M -4.50200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.97M 0.27M 0.55M 0.00800M 0.00400M
Total revenue 407.32M 333.62M 124.46M 52.16M 10.10M
Total operating expenses 408.76M 311.01M 169.94M 111.80M 163.44M
Cost of revenue 39.54M 50.56M 17.80M 4.12M 1.00M
Total other income expense net -19.65300M -10.92000M -2.24400M -3.44000M -3.81500M
Discontinued operations - - - - -
Net income from continuing ops -61.59900M -39.13600M -66.06700M -67.20700M -158.16500M
Net income applicable to common shares - - - -67.20700M -158.16500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 501.60M 435.75M 297.58M 190.07M 149.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 28.05M 27.47M 8.41M 5.11M 17.61M
Total liab 334.65M 262.46M 130.76M 91.74M 67.30M
Total stockholder equity 166.95M 173.29M 166.82M 98.33M 82.62M
Deferred long term liab - - - - -
Other current liab 66.69M 49.58M 27.64M 19.93M 12.79M
Common stock 0.02M 0.02M 0.02M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.01M
Retained earnings -946.93900M -885.34000M -846.20400M -780.13700M -712.93000M
Other liab - - - 20.28M 4.73M
Good will - - - - -
Other assets - - - 25.95M 1.15M
Cash 68.00M 64.93M 21.47M 96.14M 72.43M
Cash and equivalents - - - - -
Total current liabilities 88.61M 77.83M 50.39M 74.63M 57.55M
Current deferred revenue 1.21M 10.69M 7.18M 13.24M 4.73M
Net debt 143.60M 88.51M 34.51M -59.68000M -26.92400M
Short term debt 1.48M 1.56M 4.43M 30.61M 35.76M
Short long term debt - - - 26.71M 32.26M
Short long term debt total 211.59M 153.44M 55.98M 36.46M 45.50M
Other stockholder equity 1113.67M 1058.55M 1012.77M 878.50M 795.54M
Property plant equipment - - - 1.22M 15.11M
Total current assets 382.32M 356.45M 246.11M 154.48M 134.80M
Long term investments - - - - 0.00000M
Net tangible assets - - - 98.33M 82.62M
Short term investments 196.69M 185.17M 162.83M 27.77M 44.26M
Net receivables 71.85M 57.70M 22.03M 7.73M 0.50M
Long term debt 202.83M 150.85M 49.82M - -
Inventory 17.73M 21.17M 12.45M 3.28M 1.15M
Accounts payable 19.23M 16.00M 11.14M 10.86M 4.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.20M 0.06M 0.22M -0.05400M -0.00600M
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -780.13700M -712.93000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 112.31M 75.43M 44.87M 25.06M 1.15M
Deferred long term asset charges - - - - -
Non current assets total 119.29M 79.30M 51.47M 35.58M 15.11M
Capital lease obligations 5.12M 2.58M 6.16M 9.75M 13.24M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -7.46700M -18.31800M -100.24000M 16.67M 52.81M
Change to liabilities - - - 21.36M -0.79900M
Total cashflows from investing activities -8.95900M -18.31800M -131.24800M 18.41M 50.95M
Net borrowings 48.67M 99.45M 22.39M -6.06700M -19.44400M
Total cash from financing activities 54.51M 106.59M 146.29M 75.34M 83.00M
Change to operating activities - - - 0.91M -10.62100M
Net income -61.59900M -39.13600M -66.06700M -67.20700M -158.16500M
Change in cash 3.07M 43.46M -74.67000M 23.71M -18.60400M
Begin period cash flow 64.93M 21.47M 96.14M 72.43M 91.03M
End period cash flow 68.00M 64.93M 21.47M 96.14M 72.43M
Total cash from operating activities -42.48300M -44.80900M -89.71700M -70.04400M -152.55100M
Issuance of capital stock 0.00000M 0.00000M 138.03M 71.62M 101.15M
Depreciation 3.06M 2.06M 1.29M 1.14M 1.44M
Other cashflows from investing activities - - - 1.80M -
Dividends paid - - 25.89M - -
Change to inventory -31.92300M -41.69700M -21.14100M -28.34600M -10.37100M
Change to account receivables -14.14300M -35.67400M -14.29800M -7.23100M -0.50200M
Sale purchase of stock - 8.14M 1.17M 71.83M 102.55M
Other cashflows from financing activities 54.51M -1.00000M 4.67M 36.75M 1.30M
Change to netincome - - - 10.18M 15.17M
Capital expenditures 1.49M 1.01M 0.34M 0.06M 1.87M
Change receivables - - - -7.23100M -0.50200M
Cash flows other operating - - - -1.89600M -8.67200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 23.71M -18.60400M
Change in working capital -31.35200M -49.16900M -43.38600M -19.57500M -11.92200M
Stock based compensation 48.96M 37.38M 13.53M 10.75M 12.04M
Other non cash items -1.55300M 4.05M 4.91M 4.84M 4.25M
Free cash flow -43.97500M -45.82000M -90.06100M -70.09900M -154.41800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARDX
Ardelyx Inc		 -0.1 1.81% 5.42 - 34.97 3.59 9.26 3.65 130.88
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx Inc

400 Fifth Avenue, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Michael G. Raab Pres, CEO & Director 1965
Mr. Justin A. Renz CPA, M.S.T., MBA, MST CFO & Treasurer 1972
Ms. Elizabeth A. Grammer Chief Legal & Admin. Officer and Sec. 1964
Mr. David P. Rosenbaum Chief Devel. Officer 1961
Mr. Robert C. Blanks Chief Regulatory Affairs & Quality Assurance Officer 1960
Mr. Robert Felsch Sr. VP of Fin. & Chief Accounting Officer NA
Ms. Kimia Keshtbod Mang. of Corp. Communications & Investor Relations NA
Ms. Karen Harrigan Sr. Director Market Devel. NA
Dan Pavicich Sr. Director of Market Devel. NA
Ms. Susan Rodriguez Chief Commercial Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.